These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 28836267)

  • 1. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
    Franklin JM; Schneeweiss S
    Clin Pharmacol Ther; 2017 Dec; 102(6):924-933. PubMed ID: 28836267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergies From Integrating Randomized Controlled Trials and Real-World Data Analyses.
    Najafzadeh M; Gagne JJ; Schneeweiss S
    Clin Pharmacol Ther; 2017 Dec; 102(6):914-916. PubMed ID: 29034448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.
    Burcu M; Dreyer NA; Franklin JM; Blum MD; Critchlow CW; Perfetto EM; Zhou W
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1228-1235. PubMed ID: 32162381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing strength of evidence for regulatory decision making in licensing: What proof do we need for observational studies of effectiveness?
    Slattery J; Kurz X
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1336-1340. PubMed ID: 32301230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence.
    Fang Y; Wang H; He W
    Ther Innov Regul Sci; 2020 Jul; 54(4):749-757. PubMed ID: 32557297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Data for Clinical Evidence Generation in Oncology.
    Khozin S; Blumenthal GM; Pazdur R
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Real-world Data for New Drug Applications and Line Extensions.
    Bolislis WR; Fay M; Kühler TC
    Clin Ther; 2020 May; 42(5):926-938. PubMed ID: 32340916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews.
    Makady A; de Boer A; Hillege H; Klungel O; Goettsch W;
    Value Health; 2017; 20(7):858-865. PubMed ID: 28712614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using real-world evidence in haematology.
    Passamonti F; Corrao G; Castellani G; Mora B; Maggioni G; Della Porta MG; Gale RP
    Best Pract Res Clin Haematol; 2024 Mar; 37(1):101536. PubMed ID: 38490764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of collecting structured clinical information on multiple sclerosis.
    Ziemssen T; Hillert J; Butzkueven H
    BMC Med; 2016 May; 14():81. PubMed ID: 27246898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations.
    Hammad TA; Pinheiro SP; Neyarapally GA
    Clin Trials; 2011 Oct; 8(5):559-70. PubMed ID: 21878445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making.
    Franklin JM; Glynn RJ; Martin D; Schneeweiss S
    Clin Pharmacol Ther; 2019 Apr; 105(4):867-877. PubMed ID: 30636285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication of Oncology Randomized Trial Results using Swedish Registry Real World-Data: A Feasibility Study.
    Jemielita T; Widman L; Fox C; Salomonsson S; Liaw KL; Pettersson A
    Clin Pharmacol Ther; 2021 Dec; 110(6):1613-1621. PubMed ID: 34549809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
    Thompson D
    Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building reliable evidence from real-world data: Needs, methods, cautiousness and recommendations.
    Corrao G; Cantarutti A
    Pulm Pharmacol Ther; 2018 Dec; 53():61-67. PubMed ID: 30253238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
    Mullins CD; Sanchez RJ
    J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.
    Marchenko O; Russek-Cohen E; Levenson M; Zink RC; Krukas-Hampel MR; Jiang Q
    Ther Innov Regul Sci; 2018 Mar; 52(2):170-186. PubMed ID: 29714518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences.
    de Groot S; van der Linden N; Franken MG; Blommestein HM; Leeneman B; van Rooijen E; Koos van der Hoeven JJ; Wouters MW; Westgeest HM; Uyl-de Groot CA
    Value Health; 2017 Apr; 20(4):627-636. PubMed ID: 28408005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.